- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00363532
Functional MRI (fMRI) in CGRP Induced Migraine
Functional MRI (fMRI) in Patients With Migraine Without Aura Provoked by
In patients known with migraine without aura a migraine headache or migraine like headache will be induced by infusion of calcitonin gene related peptide (CGRP). The patients will then be stimulated with noxious heat via a thermode placed at the forehead. At the same time the Blood-oxygenation-level-dependent (BOLD) response will be measured via functional magnetic resonance imaging (fMRI), to estimate the central-nervous pain response. The regions of interest (ROI) will be thalamic region and medulla oblongata.
Then the patients will be given pain relif in form of injection of sumatriptan and the effect of this will also be registered via measuring the BOLD response at the RIO's previously defined. A 3-Tesla MRI scanner will be used in this trail.
This study will give us key knowledge of the trigeminal pain pathway and the central processing i.e sensitization during a migraine attach.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Glostrup, Denmark, 2770
- Danish Headache Center, Neurological Dep. Glostrup hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients know with migraine without aura.
- No less then 1 migraine attach pr month and no more then 6 attaches per month.
- Weight 50-100 kg.
- Women must be using secure birthcontrol.
Exclusion Criteria:
- Tension type headache more then 1 day/month.
- All other prim. og sec. headache types then migraine without aura.
- Daily use of medication other then birthcontrol pills.
- Pregnant and lactation women.
- Headache on the trail day or 5 days previous to the trail day.
- Contraindications to MRI-scans.
- Hypertension or hypotension.
- Known heart or lung condition.
- Mental illness or substance abuse.
- Other considerable conditions judged by the including doctor.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Changes in BOLD response before and after CGRP infusion.
|
|
Changes in BOLD response before and after injection of sumatriptan.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Messoud Ashina, MD,PH.d, Danish Headache Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Migraine without Aura
- Physiological Effects of Drugs
- Vasodilator Agents
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Calcitonin
- Salmon calcitonin
- Calcitonin Gene-Related Peptide
- Katacalcin
Other Study ID Numbers
- KA-20060083
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.